Physician profile
Morgan E Rabach
NPI 1013191204
$11,179.12
in general payments reported to CMS, 2019-2025
22 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,525 · 2020: $101 · 2021: $422 · 2022: $419 · 2023: $433 · 2024: $174 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,525.36 | 2019 | |
| Genzyme Corporation | $391.62 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $162.83 | 2020-2023 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $136.29 | 2021 | |
| Abbvie INC. | $123.10 | 2021-2024 | |
| Pfizer INC. | $122.69 | 2021-2023 | |
| Dermavant Sciences, INC. | $114.32 | 2022-2023 | Vtama |
| Galderma Laboratories, L.P. | $109.70 | 2020-2025 | Aklief, Oracea, Twyneo |
| Leo Pharma INC. | $65.22 | 2021-2025 | Adbry |
| Amgen INC. | $61.72 | 2021-2024 | Otezla |
| Revance Therapeutics, INC. | $54.55 | 2024 | Daxxify |
| Lilly USA, LLC | $49.21 | 2022-2023 | Olumiant |
| Vyne Pharmaceuticals INC. | $49.18 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $30.85 | 2023 | Absorica Ld, Winlevi |
| Journey Medical Corporation | $27.01 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $26.67 | 2021 | |
| Almirall LLC | $25.26 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.79 | 2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $23.89 | 2022 | |
| Mayne Pharma Commercial LLC | $20.07 | 2023 | |
| Cipher Pharmaceuticals US LLC | $17.92 | 2025 | Spinosad, Natroba |
| Botanix Sb INC | $16.87 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Rabach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.